Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
Lung Cancer
Primary: Feasibility of Pharmacogenomics-based Treatment Assignment in the Cooperative Group Setting — 71 Participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
N/A N=51 Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival at 2 Years — 69.8 percentage of participants
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 3 N=1,047 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
Phase 3 N=222 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
Phase 2 N=35 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Phase 2 N=75 Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Phase 2 N=75 Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Lung Cancer
Primary: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen — 57 Participants
Phase 2 N=59 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=120 Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose of Stereotactic Body Radiotherapy (SBRT) as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 — 12.0 Gy/FX
Phase 2 N=128 Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years
Phase 2 N=9 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Phase 2 N=33 Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Lung Cancer
Primary: Primary Tumor Control at 2 Years — 96.2 percentage of patients
Phase 2 N=22 Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
Carcinoma, Non-small Cell Lung
Primary: Response Rate Defined as the Percentage of Subjects Achieving at Least 50% Tumor Volume Reduction. — 1 Participants — p=<0.01
Phase 2 N=19 A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] — 41.2 percentage of participants
Phase 3 N=503 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Overall Survival — 0.52; 0.57 percentage of 5 years survival rate — p=0.14
Phase 2 N=48 Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Lung Cancer · Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival (PFS) — 8.7 months
Phase 2 N=60 Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance Rate — 27 participants
Phase 2 N=19 Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Toxic Death Rate — NA Participants
Phase 2 N=94 Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Counts of ≥ Grade 3 Adverse Events (AE) Graded by CTCAE v4 (Common Terminology Criteria for Adverse Events) That Are Definitely, Probably, or Possibly Related to…
Phase 3 N=1,250 A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
Non-small Cell Lung Cancer
Primary: Disease Free Survival (DFS) — 50.5; 48.2 months — p=0.3235
Phase 2 N=15 Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Phase 2 N=331 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Lung Cancer · Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung
Primary: Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC) — 5.52; 5.68; 4.63…
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96